시장보고서

상품코드

1529613

세계의 암 면역 임상시험 시장 규모, 점유율 및 동향 분석 : 단계별, 설계별, 적응증별, 지역별, 부문별 예측(2024-2030년)

Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, By Region, And Segment Forecasts, 2024 - 2030

발행일: 2024년 07월 | 리서치사:

Grand View Research | 페이지 정보: 영문 100 Pages | 배송안내 : 2-10일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

암 면역 임상시험 시장 성장 및 동향 :

Grand View Research의 최신 보고서에 따르면, 세계 암 면역 임상시험 시장 규모는 2030년까지 187억 달러에 달할 것으로 예상됩니다.

이 시장은 2024년부터 2030년까지 연평균 12.1%의 성장률을 보일 것으로 예측됩니다. 급성장하고 있는 암 면역 분야는 종양 생태계 내 새로운 치료 영역으로 부상하며 암 치료의 판도를 바꾸고 있습니다.

2014년부터 2017년까지 신규 암 면역 연구 건수는 250건에서 거의 600건으로 증가했으며, 약물의 유형이 다양해짐에 따라 매년 두 자릿수 성장률을 보이고 있습니다. 이러한 급격한 성장의 주요 요인은 바이오마커와 체크포인트 억제제 시험이었습니다. 암 면역 시장은 일부 약리학적 클래스에서 성숙하고 있지만, 세포치료제는 다른 모든 면역치료제를 능가하는 성장세를 보이고 있으며, 2020년 3월 기준 전 세계적으로 1,483개의 활성 화합물이 암 세포치료제 파이프라인에 있으며, 이는 2019년 3월 대비 472개 증가한 수치입니다. 증가한 것으로 나타났습니다. 가장 빠르게 성장하는 카테고리는 키메라 항원 수용체 T(CAR-T) 세포 제품(2019년에서 2020년 사이 77% 증가)이었습니다.

또한, 코로나19 팬데믹 기간 동안 개발 중인 IO 의약품 수는 2019년 3,876개에서 2020년 4,720개로 2019년과 2017년에 비해 각각 22%, 233% 증가했으며, 2018년과 2017년의 68%에 비해 2019년에 은 15%로 완만하게 증가했지만, 22% 증가는 코로나19의 영향에도 불구하고 IO에 대한 관심이 회복되었음을 보여줍니다.

암 면역 임상시험 시장 보고서 하이라이트

2023년 임상 3상 시험이 53.2%로 가장 큰 점유율을 차지할 것으로 예상됩니다. 일반적으로 암 분야 임상시험은 참여자 수가 적고 비용이 가장 높으며, 표본 크기가 크기 때문에 참여자 1인당 비용이 높습니다
개입 실험은 2023년 시장 점유율의 78.5% 이상을 차지했습니다
고형 종양 부문은 2023년 매출 점유율의 55.9%를 차지했습니다. 이는 고형 종양의 유병률 증가에 크게 기인합니다
북미가 2020년 50.3%의 가장 큰 매출 점유율을 차지하며 시장을 주도하고 있습니다. 이는 개인 맞춤형 의료에 초점을 맞춘 새로운 치료법의 채택 증가와 정부의 재정 지원 및 투자에 기인한 것으로 분석됩니다.

암 면역 임상시험 시장 점유율, 지역별, 2023년·2030년, 10억 달러
북미
- 북미 암 면역 임상시험 시장 추정·예측, 2018-2030년
- 미국
- 캐나다
- 멕시코
유럽
- 유럽 암 면역 임상시험 시장 추정·예측, 2018-2030년
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 아시아태평양 암 면역 임상시험 시장 추정·예측, 2018-2030년
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 라틴아메리카 암 면역 임상시험 시장 추정·예측, 2018-2030년
- 브라질
- 아르헨티나
중동 및 아프리카
- 중동 및 아프리카 암 면역 임상시험 시장 추정·예측, 2018-2030년
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

주요 시장 진출기업의 최근 동향과 영향 분석
기업 분류
기업 히트맵 분석
기업 개요
- MEDPACE
- Novartis
- Exscientia
- Syneous Health
- AstraZeneca
- IQ BIOTECH
- BioNtech
- IQVIA Holdings
- ICON, Plc
- Laboratory Corporation of America Holdings

LSH 24.08.23

Immuno-oncology Clinical Trials Market Growth & Trends:

The global immuno-oncology clinical trials market size is expected to reach USD 18.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.1% from 2024 to 2030. The rapidly growing field of Immuno-oncology has emerged as a novel therapeutic area within the oncology ecosystem, transforming the treatment of cancer.

From 2014 to 2017, the number of new immuno-oncology studies increased from 250 to almost 600, with double-digit growth rates each year as drug classes diversified. Biomarker and checkpoint inhibitor studies were primarily responsible for this rapid growth. While the immuno-oncology market is maturing in some pharmacological classes, cell therapies are exceeding all other immunotherapeutics in terms of growth. In March 2020, there were 1,483 active compounds in the pipeline for cancer cell therapy globally, indicating an increase of 472 from March 2019. The fastest-growing category was chimeric antigen receptor T (CAR-T) cell products (up 77% from 2019 to 2020).

Besides, during the Covid-19 pandemic, the number of IO drugs in development increased from 3,876 in 2019 to 4,720 in 2020, representing a 22% & 233% increase as compared to 2019 & 2017 respectively. After a moderate increase of 15% in 2019 compared to 68% between 2018 and 2017, this 22% increase indicates a return of interest in IO, despite the impact of the COVID-19 pandemic.

Immuno-oncology Clinical Trials Market Report Highlights:

Phase III dominated the market with the largest share of 53.2% in 2023. Oncology trials typically have fewer participants, are the most expensive, and involve larger sample sizes, resulting in a higher cost per participant.
The interventional experiments accounted for more than 78.5% of the market share in 2023
The segment of solid tumors held 55.9% of the revenue share in 2023. This is largely attributed to the rise in the prevalence of solid tumors
North America dominated the market and accounted for the largest revenue share of 50.3% in 2020. This is due to the rising adoption of personalized medicine-focused novel treatment methods, as well as the government funding and investments

Chapter 1. Methodology and Scope

1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
- 1.3.1. Information Procurement
- 1.3.2. Information or Data Analysis
- 1.3.3. Market Formulation & Data Visualization
- 1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
- 1.4.1. List of Data Sources

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights

Chapter 3. Immuno-oncology Clinical Trials Market Variables, Trends, & Scope

3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Billion)
3.3. Market Dynamics
- 3.3.1. Market Drivers Analysis
- 3.3.2. Market Restraints Analysis
3.4. Immuno-oncology Clinical Trials Market Analysis Tools
- 3.4.1. Porter's Analysis
  - 3.4.1.1. Bargaining power of the suppliers
  - 3.4.1.2. Bargaining power of the buyers
  - 3.4.1.3. Threats of substitution
  - 3.4.1.4. Threats from new entrants
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Economic and Social landscape
  - 3.4.2.3. Technological landscape
  - 3.4.2.4. Environmental landscape
  - 3.4.2.5. Legal landscape

Chapter 4. Immuno-oncology Clinical Trials Market: Phase Estimates & Trend Analysis

4.1. Segment Dashboard
4.2. Immuno-oncology Clinical Trials Market: Phase Movement Analysis, USD Billion, 2023 & 2030
- 4.2.1. Phase I
  - 4.2.1.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.2.2. Phase II
  - 4.2.2.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.2.3. Phase III
  - 4.2.3.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 4.2.4. Phase IV
  - 4.2.4.1. Phase IV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Immuno-oncology Clinical Trials Market: Design Estimates & Trend Analysis

5.1. Segment Dashboard
5.2. Immuno-oncology Clinical Trials Market: Design Movement Analysis, USD Billion, 2023 & 2030
- 5.2.1. Interventional Trials
  - 5.2.1.1. Interventional Trials Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.2.2. Observational Trials
  - 5.2.2.1. Observational Trials Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 5.2.3. Expanded Access Trials
  - 5.2.3.1. Expanded Access Trials Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Immuno-oncology Clinical Trials Market: Indication Estimates & Trend Analysis

6.1. Segment Dashboard
6.2. Immuno-oncology Clinical Trials Market: Indication Movement Analysis, USD Billion, 2023 & 2030
- 6.2.1. Solid Tumors
  - 6.2.1.1. Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 6.2.2. Hematological Cancer Healthcare
  - 6.2.2.1. Hematological Cancer Healthcare Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Immuno-oncology Clinical Trials Market: Regional Estimates & Trend Analysis

7.1. Immuno-oncology Clinical Trials Market Share, By Region, 2023 & 2030, USD Billion
7.2. North America
- 7.2.1. North America Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.2.2. U.S.
  - 7.2.2.1. U.S. Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.2.3. Canada
  - 7.2.3.1. Canada Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.2.4. Mexico
  - 7.2.4.1. Mexico Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.3. Europe
- 7.3.1. Europe Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.2. UK
  - 7.3.2.1. U.K. Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.3. Germany
  - 7.3.3.1. Germany Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.4. France
  - 7.3.4.1. France Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.5. Italy
  - 7.3.5.1. Italy Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.6. Spain
  - 7.3.6.1. Spain Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.7. Denmark
  - 7.3.7.1. Denmark Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.8. Sweden
  - 7.3.8.1. Sweden Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.3.9. Norway
  - 7.3.9.1. Norway Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.4. Asia Pacific
- 7.4.1. Asia Pacific Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.2. Japan
  - 7.4.2.1. Japan Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.3. China
  - 7.4.3.1. China Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.4. India
  - 7.4.4.1. India Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.5. Australia
  - 7.4.5.1. Australia Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.6. South Korea
  - 7.4.6.1. South Korea Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.4.7. Thailand
  - 7.4.7.1. Thailand Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.5. Latin America
- 7.5.1. Latin America Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.2. Brazil
  - 7.5.2.1. Brazil Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.5.3. Argentina
  - 7.5.3.1. Argentina Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
7.6. Middle East and Africa
- 7.6.1. Middle East and Africa Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.2. South Africa
  - 7.6.2.1. South Africa Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.3. Saudi Arabia
  - 7.6.3.1. Saudi Arabia Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.4. UAE
  - 7.6.4.1. UAE Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
- 7.6.5. Kuwait
  - 7.6.5.1. Kuwait Immuno-oncology Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
- 8.4.1. MEDPACE
  - 8.4.1.1. Participant's Overview
  - 8.4.1.2. Financial Performance
  - 8.4.1.3. Product Benchmarking
  - 8.4.1.4. Recent Developments/Strategic Initiatives
- 8.4.2. Novartis
  - 8.4.2.1. Participant's Overview
  - 8.4.2.2. Financial Performance
  - 8.4.2.3. Product Benchmarking
  - 8.4.2.4. Recent Developments/Strategic Initiatives
- 8.4.3. Exscientia
  - 8.4.3.1. Participant's Overview
  - 8.4.3.2. Financial Performance
  - 8.4.3.3. Product Benchmarking
  - 8.4.3.4. Recent Developments/Strategic Initiatives
- 8.4.4. Syneous Health
  - 8.4.4.1. Participant's Overview
  - 8.4.4.2. Financial Performance
  - 8.4.4.3. Product Benchmarking
  - 8.4.4.4. Recent Developments/Strategic Initiatives
- 8.4.5. AstraZeneca
  - 8.4.5.1. Participant's Overview
  - 8.4.5.2. Financial Performance
  - 8.4.5.3. Product Benchmarking
  - 8.4.5.4. Recent Developments/Strategic Initiatives
- 8.4.6. IQ BIOTECH
  - 8.4.6.1. Participant's Overview
  - 8.4.6.2. Financial Performance
  - 8.4.6.3. Product Benchmarking
  - 8.4.6.4. Recent Developments/Strategic Initiatives
- 8.4.7. BioNtech
  - 8.4.7.1. Participant's Overview
  - 8.4.7.2. Financial Performance
  - 8.4.7.3. Product Benchmarking
  - 8.4.7.4. Recent Developments/Strategic Initiatives
- 8.4.8. IQVIA Holdings
  - 8.4.8.1. Participant's Overview
  - 8.4.8.2. Financial Performance
  - 8.4.8.3. Product Benchmarking
  - 8.4.8.4. Recent Developments/Strategic Initiatives
- 8.4.9. ICON, Plc
  - 8.4.9.1. Participant's Overview
  - 8.4.9.2. Financial Performance
  - 8.4.9.3. Product Benchmarking
  - 8.4.9.4. Recent Developments/Strategic Initiatives
- 8.4.10. Laboratory Corporation of America Holdings
  - 8.4.10.1. Participant's Overview
  - 8.4.10.2. Financial Performance
  - 8.4.10.3. Product Benchmarking
  - 8.4.10.4. Recent Developments/Strategic Initiatives

세계의 암 면역 임상시험 시장 규모, 점유율 및 동향 분석 : 단계별, 설계별, 적응증별, 지역별, 부문별 예측(2024-2030년)

Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, By Region, And Segment Forecasts, 2024 - 2030

암 면역 임상시험 시장 성장 및 동향 :

암 면역 임상시험 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 암 면역 임상시험 시장 변수, 동향, 범위

제4장 암 면역 임상시험 시장 : 단계 추정·동향 분석

제5장 암 면역 임상시험 시장 : 디자인 추정·동향 분석

제6장 암 면역 임상시험 시장 : 적응증 추정·동향 분석

제7장 암 면역 임상시험 시장 : 지역 추정·동향 분석